Potential for use sunitinib in pancreatic neuroendocrine tumors
https://doi.org/10.21518/2079-701X-2019-10-115-119
Abstract
The treatment efficacy and toxicity profile was evaluated in 33 patients with highly differentiated neuroendocrine tumors NEO (G1, G2), who received sunitinib therapy in various dose regimens. Stable disease was achieved in 24 patients (72.7%), partial effect in 1 patient (3%). The efficacy of treatment did not depend on the used dose regimen. The toxicity profile was consistent with international study data.
About the Authors
A. A. Markovich
Federal State Budgetary Institution «Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation.
Russian Federation
Russian Federation
Cand. of Sci. (Med.), Senior Researcher, Scientific Advisory Department of Outpatient Diagnostic and Treatment Methods Federal State Budgetary Institution «Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation.
A. A. Kuznetsova
Federal State Budgetary Institution «Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation.
Russian Federation
Russian Federation
oncologist, Senior Researcher, Scientific Advisory Department of Outpatient Diagnostic and Treatment Methods Federal State Budgetary Institution «Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation.
V. A. Gorbunova
Federal State Budgetary Institution «Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation.
Russian Federation
Russian Federation
Dr. of Sci. (Med.), Lead Researcher, Department of Chemotherapy, Clinical Cancer Research Institute Federal State Budgetary Institution «Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation.
N. F. Orel
Federal State Budgetary Educational Institution of Additional Professional Education «Russian Medical Academy of Continuing Professional Education» of the Ministry of Health of the Russian Federation.
Russian Federation
Russian Federation
Dr. of Sci. (Med.), Professor, Chair for Oncology, Federal State Budgetary Educational Institution of Additional Professional Education «Russian Medical Academy of Continuing Professional Education» of the Ministry of Health of the Russian Federation.
A. S. Odintsova
Federal State Budgetary Institution «Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation.
Russian Federation
Russian Federation
Cand. of Sci. (Med.), Oncologist, Department of Chemotherapy, Clinical Cancer Research Institute Federal State Budgetary Institution «Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation.
G. S. Emelyanova
Federal State Budgetary Educational Institution of the Higher Education «Moscow State University of Medicine and Dentistry named after A.I. Yevdokimov» of the Ministry of Healthcare of the Russian Federation.
Russian Federation
Russian Federation
Dr. of Sci. (Med.), teaching assistant, Chair for Oncology, Federal State Budgetary Educational Institution of Higher Education «Yevdokimov Moscow State University of Medicine and Dentistry» of the Ministry of Health of the Russian Federation.
A. E. Kuzminov
Federal State Budgetary Institution «Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation.
Russian Federation
Russian Federation
Cand. of Sci. (Med.), Researcher, Department of Chemotherapy No. 1, Clinical Cancer Research Institute Federal State Budgetary Institution «Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation.
References
1. Sharma J., Duque M., Saif M.W. Emerging therapies and latest development in the treatment of unresectable pancreatic neuroendocrine tumors: an update for clinicians. Therap. Adv. Gastroenterol. 2013;6(6):474–490.
2. Fjallskog M.L., Lejonklou M.H., Oberg K.E., Eriksson B.K., Janson E.T. Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. Clin. Cancer Res. 2003;9(4):1469–1473.
3. Kulke M.H., Lenz H.J., Meropol N.J. et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J. Clin. Oncol. 2008;26(20):3403–3410.
4. Raymond E., Dahan L., Raoul J.L. et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med. 2011;364(6):501–513.
5. Faivre S., Niccoli P., Castellano D. et al. Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a Phase III randomized study. Ann. Oncol. 2016;28(2):339–343.
6. Raymond E., Kulke M.H., Qin S. et al. Efficacy and safety of sunitinib in patients with welldifferentiated pancreatic neuroendocrine tumours. Neuroendocrinology. 2018;107(3):237–245.
7. Rinzivillo M., Fazio N., Pusceddu S. et al. Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: a real-world study. Pancreatology. 2018;18(2):198–203.
8. Valle J.W., Faivre S., Hubner R.A., Grande E., Raymond E. Practical management of sunitinib toxicities in the treatment of pancreatic neuroendocrine tumors. Cancer Treat. Rev. 2014;40(10):1230–1238.
9. Valle J.W., Borbath I., Rosbrook B., Fernandez K., Raymond E. Sunitinib in patients with pancreatic neuroendocrine tumors: update of safety data. Future Oncology. 2019;15(11):1219-1230.
Review
For citations:
Markovich AA, Kuznetsova AA, Gorbunova VA, Orel NF, Odintsova AS, Emelyanova GS, Kuzminov AE. Potential for use sunitinib in pancreatic neuroendocrine tumors. Meditsinskiy sovet = Medical Council. 2019;(10):115-119. (In Russ.) https://doi.org/10.21518/2079-701X-2019-10-115-119
Views:
602
Email this article 